• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8/14/24 8:30:34 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email
    false 0000927066 0000927066 2024-08-13 2024-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 13, 2024

     

    DAVITA INC.

    (Exact name of registrant as specified in its charter)

     
         
    Delaware 1-14106 51-0354549

    (State or other jurisdiction
    of incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

    2000 16th Street

    Denver, CO 80202

    (Address of principal executive offices including Zip Code)

    (720) 631-2100
    (Registrant’s telephone number, including area code)

    Not applicable
    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 240.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class:   Trading symbol(s):   Name of each exchange on which registered:
    Common Stock, $0.001 par value   DVA   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

    On August 13, 2024 (the “Closing Date”), DaVita Inc. (the “Company”) completed the previously announced private offering (the “Notes Offering”) of $1.0 billion aggregate principal amount of its 6.875% Senior Notes due 2032 (the “2032 Notes”).

    The 2032 Notes and related subsidiary guarantees were offered and sold in a private transaction exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), to qualified institutional buyers in accordance with Rule 144A under the Securities Act and to non-U.S. persons outside of the United States pursuant to Regulation S under the Securities Act. The 2032 Notes and related subsidiary guarantees have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and other applicable securities laws.

    On the Closing Date, and as further described below, the Company also entered into an amendment (the “Sixth Amendment”) to that certain Credit Agreement, dated as of August 12, 2019 (as previously amended, restated, supplemented, or otherwise modified, and as further amended by the Sixth Amendment, the “Credit Agreement”), in each case, by and among the Company, its subsidiary guarantors, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender, to, among other things, establish an incremental tranche of senior secured term “A” loans maturing on April 28, 2028 in an aggregate principal amount of $1.1 billion (the “Incremental Term Loan A-1 Facility”).

    The Company received total net proceeds from the Notes Offering and the Incremental Term Loan A-1 Facility, after deducting the initial purchasers’ discount and other estimated fees and expenses, of approximately $2,080.7 million. On the Closing Date, the Company used such net proceeds to repay all of its approximately $950.0 million outstanding Tranche B-1 Term Loans maturing in 2026 and certain revolving loans outstanding in the amount of $60.0 million, in each case, together with related accrued and unpaid interest thereon. The Company intends to use the remaining net proceeds from the Notes Offering and Incremental Term Loan A-1 Facility to pay certain revolving loans outstanding in the amount of $350.0 million, together with related accrued and unpaid interest thereon, to pay any costs, fees and expenses in connection with the foregoing and for general corporate purposes, including, without limitation, for repurchases of its capital stock, working capital and capital expenditures.

    Indenture

    The terms of the 2032 Notes and related subsidiary guarantees are governed by an indenture, dated as of the Closing Date (the “Indenture”), among the Company, as issuer, certain subsidiaries of the Company, as guarantors (collectively, the “Guarantors”), and The Bank of New York Mellon Trust Company, N.A., as trustee (in such capacity, the “Trustee”).

    Interest and Maturity. The 2032 Notes bear interest at a rate of 6.875% per annum and mature on September 1, 2032. Interest is payable on the 2032 Notes on March 1 and September 1 of each year, commencing on March 1, 2025.

    Guarantees. The Company’s obligations under the 2032 Notes and the Indenture are jointly and severally and fully and unconditionally guaranteed by each of the Company’s domestic subsidiaries that guarantee the Company’s obligations under its existing senior secured credit facilities and any future domestic subsidiaries that guarantee indebtedness obligations of the Company or any other Company subsidiary, subject to certain exceptions set forth in the Indenture.

    Ranking. The 2032 Notes and related subsidiary guarantees are the unsecured senior obligations of the Company and the Guarantors, respectively, and (i) rank equally in right of payment with all other existing and future senior indebtedness of the Company and the Guarantors; (ii) are effectively subordinated to all existing and future secured indebtedness and secured guarantees of the Company and the Guarantors (including indebtedness and guarantees under the Company’s existing senior secured credit facilities) to the extent of the value of the collateral securing such indebtedness and guarantees; (iii) are structurally subordinated to all existing and future indebtedness, guarantees and other liabilities (including trade payables) of the Company’s subsidiaries that do not guarantee the 2032 Notes; and (iv) are senior in right of payment to all of the Company’s existing and future unsecured indebtedness that is, by its terms, expressly subordinated in right of payment to the 2032 Notes.

    Covenants. The Indenture contains restrictive covenants that limit the ability of the Company and its Guarantors to, among other things, create certain liens; enter into certain sale/leaseback transactions; or merge with or into, or convey, transfer or

     

     

    lease all or substantially all its assets. These covenants are subject to a number of important exceptions and qualifications as set forth in the Indenture.

    Events of Default. The Indenture provides for events of default (subject in certain cases to customary grace and cure periods), which include, among others, nonpayment of principal or interest when due, breach of covenants or other agreements in the Indenture, defaults in payment of certain other indebtedness and certain events of bankruptcy or insolvency. Generally, if an event of default occurs, the Trustee or the holders of at least 25% in principal amount of the outstanding 2032 Notes may declare the principal of and accrued but unpaid interest on all of the 2032 Notes to be due and payable immediately.

    Optional Redemption. At any time prior to September 1, 2027, the Company may redeem the 2032 Notes, in whole or from time to time in part, at a “make-whole” premium as set forth in the Indenture and form of 2032 Notes, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. At any time on or after September 1, 2027, the Company may redeem the 2032 Notes, in whole or from time to time in part at the redemption prices set forth in the Indenture and form of 2032 Notes, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, at any time on or prior to September 1, 2027, the Company may redeem up to 40% of the original aggregate principal amount of the 2032 Notes with the net cash proceeds of certain equity offerings, as described in the Indenture, at a redemption price equal to 106.875% of the principal amount of the 2032 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. If the Company experiences certain change of control events, the Company must offer to repurchase all of the 2032 Notes (unless otherwise redeemed) at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but excluding, the repurchase date.

    No Registration Rights or Listing. The 2032 Notes and related subsidiary guarantees do not have the benefit of any registration or similar rights. The 2032 Notes will not be listed on any securities exchange.

    The foregoing descriptions of the Indenture and the 2032 Notes do not purport to be complete and are qualified in their entirety by reference to the actual Indenture and form of 2032 Notes, copies of which are filed as Exhibits 4.1 and 4.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

    Incremental Term Loan A-1 Facility

    On the Closing Date, the Company entered into the Sixth Amendment to, among other things, establish the Incremental Term Loan A-1 Facility. The Sixth Amendment also incorporates the provisions of the Fifth Amendment to the Credit Agreement, dated as of August 7, 2024, which removed a cap on the amount of incremental term “A” loans the Company can incur under the Credit Agreement.

    Pursuant to the Sixth Amendment, borrowings under the Incremental Term Loan A-1 Facility will be denominated in U.S. dollars and will bear interest, at the Company’s option, based on (a) the Base Rate (as defined below) plus the Applicable Margin, or (b) the forward-looking term rate based on the secured overnight financing rate that is published by CME Group Benchmark Administration Limited (“Term SOFR”), plus the Applicable Margin and plus the SOFR Adjustment (as defined below). The “Base Rate” is defined as the highest of (i) the Federal Funds Rate, as published by the Federal Reserve Bank of New York, plus 50 basis points, (ii) the prime commercial lending rate of Wells Fargo as established from time to time and (iii) the Term SOFR for an interest period of one month plus 100 basis points; provided that if the Base Rate is negative it will be deemed to be zero. The “Applicable Margin” will be at a rate between 1.25% and 2.25% for loans based on Term SOFR and 0.25% to 1.25% for loans based on Base Rate, in each case based on a leverage ratio based grid. The “SOFR Adjustment” applicable to the Incremental Term Loan A-1 Facility is defined as 10 basis points per annum.

    The Incremental Term Loan A-1 Facility amortizes on a quarterly basis beginning September 30, 2024 at a rate of approximately (i) 5.0% per annum during the first three years following the Closing Date and (ii) 7.5% per annum during the fourth year following the Closing Date, with the balance to be paid on the April 28, 2028 stated maturity date of the Incremental Term Loan A-1 Facility.

    The Company and its affiliates may from time to time engage certain of the lenders under the Credit Agreement to provide other banking, investment banking and financial services.

    The foregoing description of the Incremental Term Loan A-1 Facility and the Sixth Amendment does not purport to be complete and is qualified in its entirety by reference to the actual Sixth Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Sixth Amendment has been incorporated by reference herein to provide stockholders with information regarding its terms. It is not intended to provide any other

     

     

    information about the Company or the Company’s subsidiaries that are guarantors thereunder, or other subsidiaries and affiliates of the Company. For example, the Sixth Amendment contains representations and warranties that were made solely for the benefit of the other parties to the Sixth Amendment and should not be relied upon as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries.

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

    The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    No.
      Description
         
    4.1   Indenture, dated as of August 13, 2024, by and among DaVita Inc., the subsidiary guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as trustee.
    4.2   Form of 6.875% Senior Notes due 2032 (included as Exhibit A to the Indenture filed herewith as Exhibit 4.1).
    10.1*   Sixth Amendment, dated as of August 13, 2024, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender (including a conformed copy of the Credit Agreement, reflecting all amendments through the Sixth Amendment, attached as Annex A thereto).
    104.1   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    * Schedules (or similar attachments) have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplemental copies of any of the omitted schedules (or similar attachments) upon request by the U.S. Securities and Exchange Commission.

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

      DAVITA INC.
         
    Date: August 14, 2024 By: /s/ Joel Ackerman
        Joel Ackerman
        Chief Financial Officer and Treasurer

     

     

     

    Get the next $DVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    10/29/2021$113.00 → $111.00Sector Perform
    RBC Capital
    More analyst ratings

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arway Pamela M was granted 332 shares, increasing direct ownership by 1% to 26,695 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:27 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Desoer Barbara J was granted 332 shares (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:18 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Chief Operating Officer, DKC Maughan David Paul was granted 5,308 shares and covered exercise/tax liability with 13,107 shares, decreasing direct ownership by 6% to 114,467 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:04 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    View All

    DaVita Appoints Jessica Hergenreter as Chief People Officer

    DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

    10/17/24 1:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

    DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

    9/13/24 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints New Chief Information Officer

    Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

    5/13/24 9:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    SEC Filings

    View All

    SEC Form 10-K filed by DaVita Inc.

    10-K - DAVITA INC. (0000927066) (Filer)

    2/11/26 4:06:39 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DAVITA INC. (0000927066) (Filer)

    2/2/26 4:07:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - DAVITA INC. (0000927066) (Filer)

    11/25/25 5:01:10 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on DaVita with a new price target

    Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

    3/6/24 8:09:27 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita upgraded by UBS with a new price target

    UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

    8/7/23 7:20:56 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously

    11/1/22 9:18:39 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

    Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.DENVER, March 18, 2026 /PRNewswire/ -- DaVita today highlighted continued progress in value-based kidney care, underscoring how sustained investment in coordinated care models is translating into improved outcomes for people living with kidney disease. That progress is evident across both industry partnerships with major insurers and scaled programs sponsored by the Center for Medicare & Medicaid Innovation (CMMI).For more than two dec

    3/18/26 3:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

    AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysisAlebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therapeutics, a newly launched company backed by leading global kidney care providers and life sciences strategic and venture capital investorsThe collaboration includes potential milestone payments of up to low triple-digit millions of U.S. dollars and tiered royalties in the low double-digit percentage range based on net sales of AP306 in the licensed territoryAlebund holds a substantial non-dilutive equit

    3/17/26 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

    Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal CarePartnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate Advancing Phase 2b clinical development of AP306 as a monotherapy for hyperphosphatemia in patients with chronic kidney disease on dialysis REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc ("R1"), a clinical-stage biopharmaceutical company focused on the development of first-in-class thera

    3/17/26 7:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Financials

    Live finance-specific insights

    View All

    DaVita Inc. 4th Quarter 2025 Results

    DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion

    2/2/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call

    DENVER, Jan. 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Monday, February 2, 2026 at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Monday, February 2, 2026Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen

    1/21/26 10:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 3rd Quarter 2025 Results

    DENVER, Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended September 30, 2025. "Our third quarter performance was in line with our expectations and keeps us on track to achieve our full-year guidance," said Javier Rodriguez, CEO of DaVita. "Our consistent focus on providing outstanding care is the key to these results, enabling us to continuously invest in improving the lives of our patients and supporting our dedicated teammates and physician partners." Financial and operating highlights for the quarter ended September 30, 2025: Consolidated revenues were $3.420 billion.Operating income was $506 million and adjusted operating

    10/29/25 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/13/24 5:02:42 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/9/22 3:43:35 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

    SC 13D/A - DAVITA INC. (0000927066) (Subject)

    8/4/21 4:02:59 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care